Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Wolffe A, 1998, Chromatin: Structure and function, xiv
Ling X, 1996, Yeast histone H3 and H4 amino termini are important for nucleosome assembly in vivo and in vitro: Redundant and position‐independent functions in assembly but not in gene regulation, Genes Dev, 10, 686, 10.1101/gad.10.6.686
Salnikow K, 2000, Epigenetic mechanisms of nickel carcinogenesis, J Environ Pathol Toxicol Oncol, 19, 307
Swaminathan V, 2007, Small molecule modulators in epigenetics: Implications in gene expression and therapeutics, Subcell Biochem, 41, 397
Howard G, 2007, Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice, Oncogene, 3, 404
Jones PA, 2002, The fundamental role of epigenetic events in cancer, Nat Rev, 3, 415, 10.1038/nrg816
Weber J, 1994, Expression of the MAGE‐1 tumor antigen is up‐regulated by the demethylating agent 5‐aza‐2′‐deoxycytidine, Cancer Res, 54, 1766
Plumb JA, 2000, Reversal of drug resistance in human tumor xenografts by 2′‐deoxy‐5‐azacytidine‐induced demethylation of the hMLH1 gene promoter, Cancer Res, 60, 6039
Cheson BD, 1986, A critical appraisal of low‐dose cytosine arabinoside in patients with acute non‐lymphocytic leukemia and myelodysplastic syndromes, J Clin Oncol, 4, 1857, 10.1200/JCO.1986.4.12.1857
Lewandowski K, 1995, Current approaches of treatment for myelodysplastic syndrome (MDS), Acta Haematol Pol, 26, 333
Beran M, 2000, Intensive chemotherapy for patients with high‐risk myelodysplastic syndrome, Int J Hematol, 72, 139
Beisler JA, 1976, Dihydro‐5‐azacytidine hydrochloride, a biologically active and chemically stable analog of 5‐azacytidine, Cancer Treat Rep, 60, 1671
Presant CA, 1981, Contrasting cytotoxicity kinetics of 5‐azacytidine and dihydro‐5‐azacytidine hydrochloride in L1210 leukemia in mice, J Natl Cancer Inst, 66, 1151, 10.1093/jnci/66.6.1151
Antonsson BE, 1987, Effect of 5‐azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk‐1, Cancer Res, 47, 3672
Yoo CB, 2004, Zebularine: A new drug for epigenetic therapy, Biochem Soc Trans, 32, 910, 10.1042/BST0320910
Scheinbart LS, 1991, Procainamide inhibits DNA methyltransferase in a human T cell line, J Rheumatol, 18, 530
Fang MZ, 2003, Tea polyphenol (‐)‐epigallocatechin‐3‐gallate inhibits DNA methyltransferase and reactivates methylation‐silenced genes in cancer cell lines, Cancer Res, 63, 7563
Lin X, 2001, Reversal of GSTP1 CpG island hypermethylation and reactivation of pi‐class glutathione S‐transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide, Cancer Res, 61, 8611
Segura‐Pacheco B, 2003, Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy, Clin Cancer Res, 9, 1596
Villar‐Garea A, 2003, Procaine is a DNA‐demethylating agent with growth‐inhibitory effects in human cancer cells, Cancer Res, 63, 4984
Yang ZQ, 2000, Identification of a novel gene, GASC1, within an amplicon at 9p 23‐24frequently detected in esophageal cancer cell lines, Cancer Res, 60, 4735
Johnson BA, 1993, Accumulation of substrates for protein L‐isoaspartyl methyltransferase in adenosine dialdehyde‐treated PC12 cells, J Biol Chem, 268, 6174, 10.1016/S0021-9258(18)53235-X
Hanzelka BL, 1996, Quorum sensing in Vibrio fischeri: Evidence that S‐adenosylmethionine is the amino acid substrate for autoinducer synthesis, J Bacteriol, 178, 5291, 10.1128/jb.178.17.5291-5294.1996
Garrett R, 1999, Biochemistry, 871
Roth KS, 2001, Urinary tract infections in children, Acta Paediatr Taiwan, 42, 70
Lee KK, 2007, Histone acetyltransferase complexes: One size doesn't fit all, Nat Rev, 8, 284, 10.1038/nrm2145
Polevoda B, 2002, The diversity of acetylated proteins, Genome Biol, 3, 10.1186/gb-2002-3-5-reviews0006
Muraoka M, 1996, p300 gene alterations in colorectal and gastric carcinomas, Oncogene, 12, 1565
Rowley JD, 1997, All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment‐related hematologic disorders, Blood, 90, 535
Wang HG, 1993, Identification of specific adenovirus E1A N‐terminal residues critical to the binding of cellular proteins and to the control of cell growth, J Virol, 67, 476, 10.1128/jvi.67.1.476-488.1993
Stein RW, 1990, Analysis of E1A‐mediated growth regulation functions: Binding of the 300‐kilodalton cellular product correlates with E1A enhancer repression function and DNA synthesis‐inducing activity, J Virol, 64, 4421, 10.1128/jvi.64.9.4421-4427.1990
Shankar S, 2007, Involvement of Bcl‐2 family members, phosphatidylinositol 3′‐kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)‐induced apoptosis in prostate cancer, Int J Oncol, 30, 905
Guo JJ, 2006, Histone deacetylation is involved in activation of CXCL10 upon IFNgamma stimulation, Mol Cells, 22, 163, 10.1016/S1016-8478(23)17405-X
Bi G, 2006, The molecular mechanism of HDAC inhibitors in anticancer effects, Cell Mol Immunol, 3, 285
Secrist JP, 2003, HDAC inhibitors for the treatment of cancer, Curr Opin Invest Drugs, 4, 1422
Perrine SP, 1994, Butyrate derivatives. New agents for stimulating fetal globin production in the beta‐globin disorders, Am J Pediatr Hematol Oncol, 16, 67
Kelly WK, 2003, Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously, Clin Cancer Res, 9, 3578
Sandor V, 2002, Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms, Clin Cancer Res, 8, 718
Kruh J, 1982, Effects of sodium butyrate, a new pharmacological agent, on cells in culture, Mol Cell Biochem, 42, 65
Stadtman ER, 1949, Fatty acid synthesis by enzyme preparations of Clostridium kluyveri; a consideration of postulated 4‐carbon intermediates in butyrate synthesis, J Biol Chem, 181, 221, 10.1016/S0021-9258(18)56643-6
Ota T, 2002, Increased mitotic phosphorylation of histone H3 attributable to AIM‐1/Aurora‐B overexpression contributes to chromosome number instability, Cancer Res, 62, 5168
Pascreau G, 2003, Phosphorylation of histone and histone‐like proteins by aurora kinases during mitosis, Prog Cell Cycle Res, 5, 369
Tatsuka M, 1998, Multinuclearity and increased ploidy caused by overexpression of the aurora‐ and Ipl1‐like midbody‐associated protein mitotic kinase in human cancer cells, Cancer Res, 58, 4811
Ladygina NG, 2005, Effect of the pharmacological agent hesperadin on breast and prostate tumor cultured cells, Biomed Khim, 51, 170
Leopold WR, 1984, Anticancer activity of the structurally novel antibiotic Cl‐920 and its analogues, Cancer Res, 44, 1928
Banasik M, 1992, Specific inhibitors of poly(ADP‐ribose) synthetase and mono(ADP‐ribosyl)transferase, J Biol Chem, 267, 1569, 10.1016/S0021-9258(18)45983-2
Virag L, 1999, Requirement of intracellular calcium mobilization for peroxynitrite‐induced poly(ADP‐ribose) synthetase activation and cytotoxicity, Mol Pharmacol, 56, 824
Delaney CA, 2000, Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines, Clin Cancer Res, 6, 2860
Suto MJ, 1991, Dihydroisoquinolinones: The design and synthesis of a new series of potent inhibitors of poly(ADP‐ribose) polymerase, Anticancer Drug Des, 6, 107
Abdelkarim GE, 2001, Protective effects of PJ34, a novel, potent inhibitor of poly(ADP‐ribose) polymerase (PARP) in in vitro and in vivo models of stroke, Int J Mol Med, 7, 255
Tsai YJ, 1992, Mouse mammary tumor virus gene expression is suppressed by oligomeric ellagitannins, novel inhibitors of poly(ADP‐ribose) glycohydrolase, J Biol Chem, 267, 14436, 10.1016/S0021-9258(19)49731-7
Berleth ES, 1992, Inhibition of ubiquitin‐protein ligase (E3) by mono‐ and bifunctional phenylarsenoxides. Evidence for essential vicinal thiols and a proximal nucleophile, J Biol Chem, 267, 16403, 10.1016/S0021-9258(18)42017-0
Esteller M, 2001, A gene hypermethylation profile of human cancer, Cancer Res, 61, 3225
Lo Coco F, 2002, Progress in differentiation induction as a treatment for acute promyelocytic leukemia and beyond, Cancer Res, 62, 5618